

2026 Annual General Meeting and Key Dates

SYDNEY, AUSTRALIA – 15 October 2026 – Immute Limited (ASX: IMM; NASDAQ: IMMP) ("Immute" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, advises, in accordance with ASX Listing Rule 3.13.1, that it intends to hold its 2026 Annual General Meeting ("AGM") on Friday, 27 November 2026 commencing at 11.30 am (AEDT).

Details of the format and the agenda for the AGM will be provided in the Notice of Meeting which is expected to be released later this month.

In accordance with the Company's constitution, the closing time and date for receipt of director nominations for candidates other than those recommended by the Board is 5.00 pm (AEDT) on Friday, 23 October 2026. Any nominations must be received at the Company's registered office by that time.

This announcement was authorised for release by the Company Secretary of Immute Limited.

About Immute

Immute is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immute is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immute.com.

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

US Investors/Media:

Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com

